In a recent update, Needham analyst Gil Blum has reiterated a "Buy" rating for CRISPR Therapeutics (CRSP, Financial), maintaining the price target at $81.00. The decision to uphold this rating and price target suggests continued confidence in CRISPR Therapeutics' market potential.
The current price target of $81.00 remains unchanged from the prior target, reflecting the analyst's consistent outlook on the stock's value. This analysis is significant for investors tracking CRISPR Therapeutics (CRSP, Financial) as it reinforces the company's standing as a strong investment opportunity in the biotechnology sector.
As of May 20, 2025, this rating and price target hold firm, with the stock trading on the NASDAQ exchange. Needham's affirmation of the "Buy" rating underlines the steady perspective on the stock's future performance.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 22 analysts, the average target price for CRISPR Therapeutics AG (CRSP, Financial) is $80.14 with a high estimate of $268.00 and a low estimate of $32.00. The average target implies an upside of 104.80% from the current price of $39.13. More detailed estimate data can be found on the CRISPR Therapeutics AG (CRSP) Forecast page.
Based on the consensus recommendation from 28 brokerage firms, CRISPR Therapeutics AG's (CRSP, Financial) average brokerage recommendation is currently 2.3, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for CRISPR Therapeutics AG (CRSP, Financial) in one year is $31.77, suggesting a downside of 18.81% from the current price of $39.13. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the CRISPR Therapeutics AG (CRSP) Summary page.
